Akebia Therapeutics Announces Positive Topline Results from VOCAL Trial

Article summary

Akebia Therapeutics reported that its open-label VOCAL trial met the primary endpoint of non-inferiority to standard-of-care erythropoiesis-stimulating agents (ESA) in hemodialysis patients.